Ollin Biosciences (private) announced final data from JADE study, head-to-head OLN324 compared to Vabysmo in wet AMD and DME (8:00ET) (HK$86.10, 0.00)
EU's CHMP adopted a positive opinion, recommending a change to the terms of the marketing authorisation for Retsevmo ($897.00, 0.00)
Eisai and Nuvation Bio announce EMA validation of MAA for taletrectinib in advanced ROS1+ NSCLC ($4.42, 0.00)
Innovent Biologics reports FY adjusted net income CNY1.72B vs FactSet CNY1.29B (HK$79.40, 0.00)
Federal Trade Commission clears Innovent Biologics' strategic collaboration agreement with Lilly (HK$81.55, 0.00)
FTC grants antitrust approval for Eli Lilly collaboration with Innovent Biologics (1801.HK) ($900.23, -10.32)
Innovent Biologics Phase 3 registration STAR study of efdamrofusp alfa (IBI302) meets primary endpoint (HK$77.50, 0.00)
Innovent Biologics doses first patient in phase 3 clinical study of IBI128 in gout patients (HK$81.05, 0.00)
Nuvation Bio to present pivotal IBTROZI (Taletrectinib) data in TKI-Naïve and TKI-Pretreated Patients with Advanced ROS1-Positive NSCLC at AACR 2026 ($4.40, 0.00)
StreetAccount Summary - Trading higher/lower: Hong Kong mid-morning
Powered by FactSet Research Systems Inc.